Zydus Pharmaceuticals
Zydus Pharmaceuticals, a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across North America, Europe, and Asia. Founded in 1995, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on areas such as oncology, cardiovascular health, and diabetes management. Zydus Pharmaceuticals is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that includes injectables, biosimilars, and over-the-counter medications. The company has achieved notable milestones, including numerous FDA approvals and a strong presence in the biosimilars market, positioning it as a trusted name in healthcare. With a dedication to improving patient outcomes, Zydus continues to expand its reach and impact within the pharmaceutical landscape.
DitchCarbon Score
How does Zydus Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Pharmaceuticals's score of 30 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zydus Pharmaceuticals's reported carbon emissions
In 2023, Zydus Pharmaceuticals reported total carbon emissions of approximately 6,650,000 kg CO2e for Scope 1 and about 8,969,000 kg CO2e for Scope 2. This indicates a significant commitment to tracking and managing their greenhouse gas emissions. In the previous year, 2024, the company recorded higher emissions, with Scope 1 at approximately 31,304,000 kg CO2e and Scope 2 at about 8,798,000 kg CO2e. Despite these figures, Zydus Pharmaceuticals has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets suggests that while the company is monitoring its emissions, it may not yet have formalised a comprehensive strategy for significant reductions. Overall, Zydus Pharmaceuticals is actively engaged in emissions reporting, but further commitments and initiatives will be essential for aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 6,650,000 | 00,000,000 |
| Scope 2 | 8,969,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
